Hospital EMR Systems Market by Component (Software, Services, Hardware), Delivery Mode (Cloud, On-premise), Type (Specialty EMR), Hospital Size (Small, Large Hospitals) and Region (North America, Europe, Asia Pacific) – Global Forecast to 2025

2020-06-12
Price :
Published : Jun-2020
No. of Pages : 187

The global hospital EMR systems market is projected to reach USD 20.7 billion by 2025 from USD 14.2 billion in 2020, at a CAGR of 7.8% during the forecast period. There is a growing inclination across the globe towards the adoption of EMR systems due to government support for the adoption of EMRs, an increase in the COVID-19 patient volume, and the rising need to curtail healthcare costs.

By component, the services segment accounted for the largest market share in 2019.

Based on components, the hospital EMR systems market is segmented into services, software, and hardware. The services segment accounted for the largest market share in 2019. The introduction of complex software and the need for software integration and interoperability, which require extensive training and regular upgrades, are the major factors responsible for the large share of the services segment.

By delivery mode, the on-premise segment accounted for the largest share of the hospital EMR systems market in 2019.

Based on the delivery mode, the hospital EMR systems market is segmented into on-premise and cloud-based solutions. The cloud-based segment is expected to be the fastest-growing segment during the forecast period. An increasing number of hospitals have shifted their preference from on-premise models to cloud-based models, which has contributed towards its market growth.

By type, the general EMR solutions segment accounted for the largest share of the hospital EMR systems market in 2019.

Based on type, the market is segmented into general EMR and specialty EMR solutions. In 2019, the general EMR solutions segment accounted for the largest share of the hospital EMR systems market. The large share of this market segment can be attributed to the multifunction, multi-specialty capabilities of general EMRs, enabling their use in various specialties through flexible functioning and incorporated plugins.

By hospital size, the small and medium-sized hospitals segment accounted for the largest share of the hospital EMR systems market in 2019.

Based on hospital size, the hospital EMR systems market is segmented into small and medium-sized hospitals and large hospitals. In 2019, the small and medium-sized hospitals segment accounted for the largest share of the market. The large share of this segment can be attributed to the faster adoption of EMRs in small and medium-sized hospitals owing to factors such as ease of transfer of patient data among healthcare providers, lower upfront costs, and ease of deployment.

The breakdown of primary participants is mentioned below:

  • By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
  • By Designation: C-level (40%), Director-level (35%), and Others (25%)
  • By Region: North America (40%), Europe (20%), APAC (30%), Latin America (8%), and the Middle East & Africa (2%)

The prominent players in the hospital EMR systems market are Cerner Corporation (US), Epic Systems Corporation (US), Allscripts Healthcare Solutions, Inc. (US), MEDITECH (US), CPSI (US), GE Healthcare (US), athenahealth, Inc. (US), MEDHOST (US), eClinicalWorks (US), NextGen Healthcare (US), Intersystems Corporation (US), MTBC (US), Cantata Health (US), Advanced Data Systems Corporation (US), and CureMD (US).

Research Coverage:

The report analyzes the hospital EMR systems market and aims at estimating the market size and future growth potential of this market based on various segments, such as components, delivery mode, type, hospital size, and region. It also covers the competitive leadership mapping, which helps in analyzing the position of key market players as stars, emerging leaders, pervasive players, and emerging companies. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the hospital EMR systems market. The report analyzes this market by component, delivery mode, type, hospital size, and region
  • Product Enhancement/Innovation: Detailed insights on the upcoming trends and service launches in the hospital EMR systems market
  • Market Development: Comprehensive information on the lucrative emerging markets by component, delivery mode, hospital size, type, and region
  • Market Diversification: Exhaustive information about new testing services, recent developments, and investments in the hospital EMR systems market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, service offerings, and capabilities of leading players in the hospital EMR systems market
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Teleradiology Market by Products & Services (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers & Laboratories), COVID-1 Impact – Forecast to 2025

“Dearth of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 22.8 billion by 2025 from USD 7.9 billion in 2020, at a CAGR of 23.5% during the forecast period of 2020 to 2025. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the rising geriatric population and the subsequent increase in the prevalence of associated diseases, the increasing adoption of cloud-based solutions, and the benefits offered by teleradiology and a dearth of skilled radiologists. However, declining reimbursements and increasing regulatory burden in the US and data breaching of imaging report hampered market gr......
$5650

Coronavirus Disease 2019 – Epidemiology Analysis and Forecast – June 2020

Coronavirus Disease 2019 - Epidemiology Analysis and Forecast - June 2020 Summary The pandemic's epicenters have shifted to Latin America, India, Pakistan, and South Africa. COVID-19 is mainly affecting the dense populous and poorer regions of these countries. As a result, the global daily confirmed cases are increasing at a higher pace than before. The US continues to be the most affected country globally, reaching close to 2.5 million cases. The US reported the highest number of new daily cases on 26 June since the start of the pandemic. Chile moves up ahead of Spain. Brazil has now reported more than 1 million total confirmed cases of COVID-19. Mexico is now ranked 11th among the top most affected countries. The report covers current epidemiology situation, forecast, and analysis ......
$1995

Amyloidosis – Epidemiology Forecast to 2029

Amyloidosis - Epidemiology Forecast to 2029 Summary Amyloidosis is a rare disease characterized by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alters the normal functions of the tissues in the organs (Holmes et al., 2019; Mayo Clinic, 2020). Amyloid is not normally found in the body, but it can be formed from several different types of protein and interferes with the organs' normal function. Organs that may be affected by amyloidosis include the heart, kidneys, liver, spleen, nervous system, and digestive tract (Mayo Clinic, 2020). The signs and symptoms of amyloidosis include dizziness, fluid retention, fatigue, fainting, an enlarged tongue, low blood pressure, and shortness of breath (Mayo Clinic, 2020; Stanford Health Care, 2020). There ar......
$3995

Transthyretin Amyloidosis – Global Drug Forecast and Market Analysis to 2029

Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029 Summary Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis diagnoses are made later in life, with the average patient aged 65 at diagnosis. Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein an......
$10995

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......
$695

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......
$10995

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......
$3995

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......
$4950

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......
$995

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
$595
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy